Roche Holding AG
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-20.1% vs price
Base Case (Median)
42.1% vs price
Bull Case (75th pct.)
73.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $842.12 | 104.8% | High (40%) |
| PE Comparable | $584.48 | 42.1% | Medium (25%) |
| Growth Trajectory DCF | $682.47 | 66.0% | Medium (20%) |
| Graham Number | $158.77 | -61.4% | Medium (40%) |
| EV/EBITDA | $284.77 | -30.8% | Medium (20%) |
| EV/FCF | $745.51 | 81.3% | Medium (20%) |
| Earnings Power Value | $372.37 | -9.5% | Medium (50%) |
Based on 7 out of 8 methods, RHHVF appears fairly valued at the current price of $411.25. The base case fair value of $584.48 implies 42.1% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.